tecotabart vedotin (LM-302)

News alerts, weekly reports and conference planners

Company:

LaNova Medicines Limited

Drug class:

Microtubule inhibitor, CLDN18.2-targeted antibody-drug conjugate

CLDN18.2 underexpression	Pancreatic Cancer	CLDN18.2 underexpression	Pancreatic Cancer	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D
CLDN18.2 overexpression	Pancreatic Cancer	CLDN18.2 overexpression	Pancreatic Cancer	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D
CLDN18.2 overexpression	Gastric Cancer	CLDN18.2 overexpression	Gastric Cancer	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D	LM-302 Sensitive: D – Preclinical LM-302 Sensitive : D

Associations
(3)